Breakthroughs on the Horizon for CTE and Other Neurodegenerative Diseases

from SEC by Fred Zucker

The quest to address long-term neurodegenerative problems associated with traumatic brain injury (TBI) and concussions has received plenty of attention recently, in part because of high profile athletes raising awareness and also because of some breakthrough research by Boston University and the University of California at Los Angeles.  With any advancement come arguments on both sides of the debate about the accuracy of statements without extensive clinical research, and the sobering reality is that there still are no reliable treatments for diseases like Alzheimer’s disease and chronic traumatic encephalopathy (CTE).  All scientific posturing and argumentative rhetoric aside, the fact that companies are making strides in diagnostics and more resources are being devoted to these areas of tremendous unmet medical need are reason for optimism as there are new paths being carved in the evolution of new treatments.

In the public domain, the majority of companies steer clear of neurological conditions because of the elusive nature of answers and the often non-linear progression of these diseases that can make research extremely challenging.  The other side of that coin is that successful research can reap tremendous returns from both corporate and humanitarian perspectives.  Companies like Neuralstem, Inc. (NYSE MKT: CUR) and Aethlon Medical, Inc. (OTCBB: AEMD) are not shying away from the challenge and appear to be making substantive progress.

(read more…)

Leave a Reply

Your email address will not be published. Required fields are marked *